TABLE 1.
Unweighted and weighted discovery cohort patient characteristics stratified by immunosuppressant (IS) exposure
| Discovery cohort | Weighted discovery cohort | ||||||
| IS exposed (n=278) | IS unexposed (n=335) | p-value | IS exposed (n=286) | IS unexposed (n=332) | p-value | SMD | |
| Centre | <0.01 | 0.62 | 0.13 | ||||
| UTSW | 171 (62) | 157 (47) | 138 (48) | 171 (51) | |||
| UCSF | 34 (12) | 51 (15) | 56 (19) | 50 (15) | |||
| Chicago | 69 (25) | 119 (36) | 88 (31) | 105 (32) | |||
| UCD | |||||||
| CUMC | 4 (1) | 8 (2) | 4 (2) | 6 (2) | |||
| ILD diagnosis | 0.10 | 0.91 | 0.04 | ||||
| fHP | 75 (27) | 81 (24) | 73 (25) | 83 (25) | |||
| CTD-ILD# | 114 (41) | 119 (36) | 107 (37) | 131 (39) | |||
| uILD | 89 (32) | 135 (40) | 106 (37) | 118 (36) | |||
| Age, years | 60±11 | 63±12 | 0.01 | 62±10 | 62±12 | 0.93 | 0.01 |
| Male | 113 (41) | 129 (39) | 0.65 | 109 (38) | 128 (39) | 0.93 | 0.01 |
| Ethnicity/race | 0.58 | 0.76 | 0.03 | ||||
| White | 204 (73) | 226 (68) | 196 (68) | 232 (70) | |||
| African American | 37 (13) | 59 (18) | 43 (15) | 59 (18) | |||
| Hispanic | 27 (10) | 37 (11) | 30 (10) | 32 (10) | |||
| Asian | 9 (3) | 12 (4) | 17 (6) | 9 (3) | |||
| Other¶ | 1 (0) | 1 (0) | 1 (0) | 1 (0) | |||
| Ever-smoker | 130 (47) | 178 (53) | 0.14 | 151 (53) | 172 (52) | 0.81 | 0.02 |
| Family history of ILD | 32 (12) | 31 (9) | 0.43 | 26 (9) | 31 (9) | 0.94 | 0.01 |
| Lung function | |||||||
| FVC % pred | 62±17 | 69±20 | <0.01 | 66±18 | 66±19 | 0.97 | <0.01 |
| DLCO % pred | 42±19 | 48±20 | <0.01 | 45±19 | 45±20 | 0.77 | 0.03 |
| Radiographic features | |||||||
| UIP+ | 54 (19) | 78 (23) | 0.29 | 61 (21) | 72 (22) | 0.92 | 0.01 |
| Honeycombing | 75 (27) | 121 (36) | 0.02 | 78 (27) | 112 (33) | 0.15 | 0.11 |
| IS therapy | |||||||
| Mycophenolate | 179 (64) | 184 (64) | |||||
| Azathioprine | 99 (36) | 102 (36) | |||||
| IS exposure, years | 1.7 (0.7–2.0) | 1.9 (0.6–2.0) | |||||
| Prednisone | 231 (83) | 143 (43) | <0.01 | 169 (60) | 201 (61) | 0.77 | 0.03 |
| LTL | |||||||
| LTL <10th percentile | 57 (21) | 65 (19) | 0.81 | 51 (17) | 65 (20) | 0.52 | 0.06 |
| Age-adjusted LTL | −0.1 (−0.3–0.1) | −0.1 (−0.3–0.1) | 0.39 | −0.1 (−0.2–0.1) | −0.1 (0.3–0.1) | 0.55 | 0.06 |
| Follow-up, years | 2.0 (1.4–2.0) | 2.0 (1.3–2.0) | 0.73 | 2.0 (1.3–2.0) | 2.0 (1.8–2.0) | 0.32 | <0.01 |
| Outcome | |||||||
| Death within 2 years | 42 (15) | 31 (9) | 0.04 | 41 (14) | 29 (9) | 0.06 | 0.18 |
| Transplant within 2 years | 15 (5) | 5 (2) | 0.01 | 11 (4) | 4 (1) | 0.02 | 0.17 |
Data are presented as n (%), mean±sd or median (interquartile range). SMD: standardised mean difference; UTSW: University of Texas Southwestern; UCSF: University of California San Francisco; Chicago: University of Chicago; UCD: University of California Davis; CUMC: Columbia University Medical Center; ILD: interstitial lung disease; fHP: fibrotic hypersensitivity pneumonitis; CTD: connective tissue disease; uILD: unclassifiable ILD; FVC: forced vital capacity: DLCO: diffusing capacity of the lung for carbon monoxide; UIP: usual interstitial pneumonia; LTL: leukocyte telomere length. #: CTD-ILD diagnoses: scleroderma n=63, rheumatoid arthritis n=69, inflammatory myositis n=36, mixed CTD n=32, Sjögren's syndrome n=24, systemic lupus erythematosus n=10; ¶: other ethnicity/race: unknown n=2; +: radiographic UIP incudes definite UIP.